What is ANNX stock price today?

ANNX (Annexon Inc) stock is trading at $6.35 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ANNX stock going up or down today?

ANNX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ANNX stock now?

The decision to buy ANNX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ANNX a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ANNX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ANNX stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ANNX is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ANNX's P/E ratio?

P/E ratio data for ANNX will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ANNX's market cap?

ANNX (Annexon Inc) has a market capitalization of $0.93 billion, making it a small-cap stock.

What is ANNX's price to book ratio?

ANNX trades at a price-to-book (P/B) ratio of 4.40, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ANNX pay dividends?

ANNX does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ANNX's dividend yield?

ANNX does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ANNX stock a good long-term investment?

ANNX's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ANNX's revenue growth rate?

Revenue growth data for ANNX is available on our dashboard with detailed financial statement analysis.

Profitability metrics for ANNX are available on our dashboard with complete income statement analysis.

What are the risks of investing in ANNX?

Key risks for ANNX include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ANNX compare to its competitors?

Compare ANNX to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ANNX's performance and positioning.

What is ANNX's stock price target for 2026?

Our AI model provides price targets for ANNX based on fundamental analysis: Bull case $8.25 (+30%), Base case $7.30 (+15%), Bear case $5.71 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ANNX?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ANNX. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ANNX's next earnings report?

ANNX reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ANNX - Annexon Inc

NYSE * Health Care * Biotechnology

$6.35

+$0.55 (+9.48%)

About Annexon Inc

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

ANNX Key Statistics

Market Cap

$930.75M

P/B Ratio

4.40

EPS

$-1.34

Employees

How ANNX Compares to Peers

ANNX is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ANNX(This stock)	$930.75M	N/A	0%	0.0%	-
AMGNAmgen Inc	$189.19B	24.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$174.33B	20.7	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.01B	29.0	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.87B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.50B	20.5	-0%	0.1%	vs BIIB

Annexon Inc Company Information

Headquarters: California; U.S.A
Website: www.annexonbio.com
Sector: Health Care
Industry: Biotechnology

ANNX - Annexon Inc

About Annexon Inc

ANNX Key Statistics

How ANNX Compares to Peers

Annexon Inc Company Information

ANNX Lician Score

ANNX Financial Snowflake

Upcoming Events for ANNX